Protagonist Therapeutics, Inc. PTGX R2KR3KPHARMA
Company Overview
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Why Investors Should Care
Revenue has grown at a 12.6% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $46.02M (-89.4% YoY); net profit $-130.15M.
- Trailing 12 Months Year-on-year growth — revenue +99.0%, earnings -147.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 12.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 12.59% |
| 1 Year: | 99.00% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -147.29% |
Stock Price Performance
| 1 Year: | +156.91% |
| 6 Months: | +58.24% |
| 3 Months: | +49.64% |
| 1 Month: | -0.31% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)49.35 · Neutral
P/E of 142.86 is above the sector median of 25.17 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 12.6% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 142.9.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PTGX Protagonist Therapeutics, Inc. R2KR3KPHARMA | 145.72 | 142.86 | $9.43B | 0.00% | -25.39% | -17.06% | 12.59% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 0 | - | - | - | 8.78M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 28.32M | 5.55M | 4.71M | 7.44M | 56.37M | 213.47M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 47.63M | 47.59M | 51.13M | 57.79M | 60.02M | - |
| Operating Income | -3.08M | -4.02M | -5.00M | -7.04M | -7.09M | -7.14M | -11.40M | -14.27M | -15.13M | -4.98M | -3.51M | -8.23M | -9.24M | -9.39M | -15.41M | -14.65M | -31.41M | -17.17M | -17.30M | -19.70M | -18.22M | -7.77M | -24.02M | -30.88M | -33.93M | -21.11M | -41.44M | -32.30M | -36.02M | -42.35M | -38.33M | 206.31M | -38.79M | -41.45M | -19.31M | -42.04M | -46.42M | -50.35M | -3.65M | 158.77M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -19.07M | -41.74M | -46.06M | -49.98M | -3.24M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -11.65M | -34.60M | -39.34M | -43.72M | 2.28M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 172.00K | 0 | 666.00K | -1.50M | - |
| Net Income | -3.22M | -3.45M | -5.49M | -11.75M | -7.10M | -7.08M | -11.25M | -14.10M | -14.98M | -4.83M | -3.05M | -7.66M | -8.66M | -8.73M | -13.87M | -14.10M | -29.17M | -16.41M | -17.50M | -20.08M | -19.42M | -7.76M | -24.00M | -30.84M | -33.80M | -20.93M | -41.04M | -31.23M | -33.73M | -38.46M | -34.10M | 207.34M | -30.62M | -33.21M | -11.65M | -34.77M | -39.34M | -44.38M | 3.78M | 162.85M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.54 | -0.69 | -0.70 | -0.43 | -0.84 | -0.64 | -0.67 | -0.68 | -0.58 | 3.26 | -0.50 | -0.54 | -0.19 | -0.55 | -0.62 | -0.69 | 0.05 | 2.29 |
| R&D Expense | 2.30M | 3.16M | - | 5.62M | 5.70M | 5.56M | - | 11.28M | 12.01M | 11.17M | - | 15.37M | 17.73M | 12.14M | - | 12.44M | 19.36M | 17.29M | - | 18.77M | 20.26M | 15.99M | 24.25M | 26.43M | 36.96M | 36.32M | 34.61M | 25.40M | 27.42M | 33.18M | 30.66M | 33.73M | 33.52M | 35.97M | 35.89M | 37.04M | 40.00M | - | 46.74M | 42.06M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 20.06M | 30.93M | 231.00K | 28.63M | - | 26.58M | 60.00M | 434.43M | 46.02M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | 157.95M | 153.65M | 181.59M | 204.14M |
| Operating Income | -9.32M | -14.79M | -32.67M | -37.90M | -42.27M | -80.52M | -64.52M | - | -131.37M | -93.65M | 252.84M | -158.13M |
| EBITDA | - | - | - | - | - | - | - | - | -130.34M | -92.67M | 253.67M | -156.85M |
| Interest Expense | - | - | - | - | - | - | - | 0 | 0 | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | -127.39M | -78.95M | 279.41M | -129.31M |
| Tax Provision | - | - | - | - | - | - | - | - | 0 | 0 | 4.22M | 838.00K |
| Net Income | -11.07M | -14.86M | -37.18M | -36.96M | -38.92M | -77.19M | -66.15M | - | -127.39M | -78.95M | 275.19M | -130.15M |
| Diluted EPS | - | - | - | - | - | - | -1.92 | - | -2.60 | -1.39 | 4.23 | -2.05 |
| R&D Expense | 7.46M | 11.83M | 25.70M | 46.18M | 59.50M | 65.00M | 74.51M | 126.01M | 126.22M | 120.16M | 138.13M | 159.29M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 14.85M | 93.99M | 163.73M | 139.47M | 154.92M | 324.47M | - | 247.93M | 357.95M | 744.73M | 668.19M |
| Current Assets | - | - | - | - | - | - | - | - | - | 243.08M | 355.58M | 591.64M | 577.57M |
| Cash & Equivalents | 8.46M | 9.32M | 4.05M | 21.08M | 106.03M | 82.23M | 33.01M | 117.36M | - | 125.74M | 186.73M | 97.25M | 128.39M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | 52.00K | 10.33M | 168.49M | 4.50M |
| Total Liabilities | - | - | 5.25M | 6.43M | 43.10M | 26.96M | 74.95M | 44.86M | - | 32.32M | 21.27M | 69.43M | 53.48M |
| Current Liabilities | - | - | 3.13M | 6.43M | 42.55M | 26.16M | 35.41M | 40.24M | - | 31.18M | 21.27M | 47.40M | 45.44M |
| Long Term Debt | - | - | - | - | - | - | 9.79M | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | 3.66M | 1.14M | 10.87M | 10.32M |
| Total Equity | -1.39M | -12.62M | -27.40M | 87.56M | 120.63M | 112.52M | 79.96M | 279.61M | - | 215.61M | 336.68M | 675.29M | 614.71M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | 49.34M | 57.71M | 61.04M | 62.58M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | -14.38M | -29.97M | 3.87M | -49.95M | -41.53M | -72.48M | -107.86M | -108.14M | -70.24M | 184.15M | 57.67M |
| Investing Cash Flow | - | -8.26M | -59.33M | 15.82M | 2.21M | -53.71M | -90.97M | -15.86M | 91.47M | -39.26M | -299.48M | -49.33M |
| Financing Cash Flow | - | 17.42M | 106.31M | 65.55M | 24.11M | 46.04M | 247.63M | 129.92M | 18.84M | 170.48M | 25.85M | 22.86M |
| Capital Expenditure | -299.00K | -399.00K | -347.00K | -666.00K | -486.00K | -967.00K | -471.00K | -1.10M | -795.00K | -609.00K | -1.35M | -1.59M |
| Free Cash Flow | - | -14.78M | -30.32M | 3.21M | -50.43M | -42.49M | -72.95M | -108.97M | -108.93M | -70.84M | 182.80M | 56.08M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | -188.9% | -136.7% | -34,857.6% | -225.4% | - | -494.2% | -156.1% | 58.2% | -343.6% |
| Net Margin % | - | - | - | -184.2% | -125.9% | -33,414.3% | -231.1% | - | -479.3% | -131.6% | 63.3% | -282.8% |
| ROE % | 87.7% | 54.2% | -42.5% | -30.6% | -34.6% | -96.5% | -23.7% | - | -59.1% | -23.5% | 40.8% | -21.2% |
| ROCE % | - | -126.2% | -37.3% | -31.3% | -37.3% | -67.4% | -22.7% | - | -60.6% | -27.8% | 36.3% | -25.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 15.93% | 10.31M | $1.49B |
| 2 | Farallon Capital Management LLC | 9.81% | 6.35M | $916.34M |
| 3 | RTW Investments LP | 7.82% | 5.06M | $730.48M |
| 4 | Vanguard Portfolio Management LLC | 5.61% | 3.63M | $523.82M |
| 5 | Wellington Management Group, LLP | 5.28% | 3.42M | $493.14M |
| 6 | UBS Group AG | 5.25% | 3.40M | $490.61M |
| 7 | State Street Corporation | 5.13% | 3.32M | $479.40M |
| 8 | Vanguard Capital Management LLC | 4.41% | 2.85M | $411.83M |
| 9 | Johnson & Johnson | 3.78% | 2.45M | $353.49M |
| 10 | Invesco Ltd. | 3.62% | 2.34M | $337.83M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PTGX
How Investors Are Reacting To Protagonist Therapeutics (PTGX) Turning ICOTYDE Milestones Into Q2 Profit - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi8AFBVV95cUxNcWJLNGRVVWtCTkFaWDd1SjJCdjNGVlpLYUtJWmRQaU5OWENtZEVmeVNOc1JaNE9KM1p5b3lpMWN0OEtuaTA5S3BlU2dqTDNmSmVzUVNLTlFVU2hnOUQ0cUlBTV9QWnVmZUJYbFM1Q2tzLUVIWmQzVjBVZjRSdmpUZEc3S1BMYm9xTkpxaW…
Protagonist Therapeutics (PTGX) Stock Could Be Overvalued Following FDA Approval News - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxNNEcwX3RFSWJHNXFQWVdIVHJtbWRCbjNCNXZvUzI0MHVRTDlnSVI4Qnh4UXY2UWEwcDNSN1RyTklCOXFlc25nbTk4SGRCUGhkVlNJcUtQbVZwdTBVUU0wRUdtQ3MxTlVOQ294MzJhZTAxQkYxYVM2QjJLazc2WFVncF9mTWRHZ2N2U05yOH…
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMi_wFBVV95cUxPWU9yUjVET1pPVVBKNTVnTWIxbmFleHVoa2ZLWjV0U3l1bDhsZW5iLTRpbDlBODlaWnN5RS1Kbmw2d19tZ3lSRGZwTGZJTVJmazJMbjlRZlRtSFhhNHJLRHlZVGEtMG1pQUdpNGc4RXlvaUptN2d6RnBfQWExTXFQY2N1V3IzWnF5UDl5dk…
Protagonist Therapeutics (PTGX) Stock Looks Fully Priced After Its 7x Run - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxQWFBEOXk0QS1TRV96SEhYSTQ5Skc5LXZfNTR4ZUR3cVE5OVIyLXBoTUpmbkxtamo4c3dvRHdlV0VuSVJwdE44M0U3RjJQdXRXTGhIWW5hUzRHdk80dUVXWG1zQnVhLUlIalBBRHVJOE1hOGs0Z1czV0prazh1TVVSaU5mcEQ4MlJELWpneH…
Protagonist (PTGX) Swings To A Profit As Two Drugs Near Blockbuster Status - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxQamZESVk2MVpIbFlrWGx5SV84RDk1VGRXdXpDR3VURU1vc1VnbHE1YURKMWdkemh5SE1ES3ljTW55cExnWkdoMENlTmsxNTBiZmVXemdqeDRCNkF5V3dubHFMcW9Oa3dwR19LSnk5OGZBZWZUc3NHN004Y1lnOThUVF82UWxwd3IzdzhlWE…
Protagonist Therapeutics(PTGX.US) Officer Sells US$7.51 Million in Common Stock - Moomoo
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxOcGtaYVlZSGVIX2RCNHQ1VTdEazZqYXd0Mjh4cl9ZR0VaYkpSbUM4VEdSTDVaSjh4cDIzbDgweVQxTHMwWmRkNnpyMTAwZWhsbW02bTJjRFhjVWFDZ0FTb29udWstR2pyYlZnS1czdkVsaUdHbXBCQmpaQTNZckNqQngzTURtNXd3al9kMy…
PTGX — Frequently Asked Questions
What is the current share price of Protagonist Therapeutics, Inc. (PTGX)?
As of 2026-09-07 16:24 PDT, Protagonist Therapeutics, Inc. (PTGX) trades at $145.72 on NasdaqGM. Its 52-week range is $54.99 to $158.62.
What is the market capitalisation of PTGX?
Protagonist Therapeutics, Inc. (PTGX) has a market capitalisation of $9.43B on NasdaqGM.
What is the P/E ratio of PTGX?
PTGX trades at a trailing price-to-earnings (P/E) ratio of 142.86. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 14.29.
What is the return on equity (ROE) of PTGX?
PTGX has a return on equity (ROE) of -17.06%. Its return on capital employed (ROCE) is -25.39%.
Is PTGX a good stock to buy?
This page provides a data-driven analysis of Protagonist Therapeutics, Inc. (PTGX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.